ADVA
21.1.2020 09:02:12 CET | Business Wire | Press release
ADVA (FSE: ADV) today announced that it has successfully demonstrated Europe’s first 5G rail deployment in an operational environment. Using a combined optical and microwave transport solution, the demo succeeded in delivering multi-Gbit/s connectivity to fast-moving trains. Until now, supporting the handovers required for consistent broadband connectivity on trains traveling at speed was a major challenge. Built on ADVA’s G.metro passive optical technology and FSP 150 edge aggregation solution , the joint trial featured an integrated architecture for all train communication applications. Millimeter wave (mmWave) access points (APs) were used to maintain track-to-train connectivity as well as programmable mobility functions for seamless onboard services. Part of the EU’s Horizon 2020 5G-PICTURE project, the demo was conducted by ADVA, Blu Wireless Technology, CNIT, COMSA Industrial and the local railway operator and infrastructure manager, Ferrocarrils de la Generalitat de Catalunya (FGC).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200121005201/en/
“With this demo, we’ve presented the blueprints for the future of rail telecommunication networks. We’ve shown how a combined optical and microwave 5G architecture can carry both critical and non-critical communications, dramatically simplifying deployments and delivering significant cost reduction,” said Jim Zou, senior engineer, advanced technology, ADVA. “Unlike traditional railway telecommunication networks that rely on separate infrastructures, what we’ve proposed with this demo is a unified, automated network able to support every application and prevent service interruptions. It delivers high-bandwidth internet access to passengers on the move, while also providing train operators with driver-to-control connectivity, access to surveillance cameras and mission-critical onboard applications. Now a single 5G network can provide all telco services for train companies, freight operators and passengers.”
Deployed across three stations of the FGC network in Barcelona, the 5G-PICTURE railway testbed interconnected a variety of end-user devices and compute resources using the most advanced optical and wireless network technologies. For the first time in Europe in a live operational scenario, the demo proved that a single integrated infrastructure can deliver safe, secure and reliable connectivity for all three categories of train line services: critical, performance and business. Along the track, it leveraged mmWave links that intelligently steered beams to the train’s rooftop antennae for optimal backhaul and access connectivity. These were connected to passive WDM add/drop nodes built with ADVA’s low-latency G.metro system and each mmWave AP was capable of dedicated 10Gbit/s connectivity. All the traffic from the trackside was further aggregated to the railway operator’s core network based on ADVA’s 100Gbit/s Ethernet aggregation technology.
“At FGC, we understand the value of leveraging emerging technology to achieve maximum efficiency and provide our passengers with the best available services. That’s why we’re so excited by the possibilities that this demo presents. It showed how we can harness an intelligent, open and scalable 5G network for everything from surveillance to passenger communications to mission-critical operational data transport,” commented Carles Terés Casals, director, R&D, FGC. “Train passengers are heavy users of mobile data. Whether it’s video streaming, replying to emails and social media or planning the next stage of their journey, they expect always-on access to advanced services. Providing ultra-reliable high-speed mobility on a virtual infrastructure shared with all other applications offers a way to meet that demand while removing complexity and saving significant cost.”
“This project is about completely transforming on-train connectivity for the digitalization strategy of the railway sector. It’s about providing massive high-quality wireless capacity to trains to enable cloud-based applications that improve performance and security in the railway sector. It’s also about being able to support new business and passenger applications,” said Manuel Alfageme, head of smart systems innovation, COMSA Industrial. “At COMSA, we have a formidable record of leading the way with rail innovation. By jointly demonstrating the technical and commercial viability of this technology in a live operational environment, we’re showing train operators and railway infrastructure managers that open, scalable and agile 5G networks are now possible in the railway vertical. The time has come for a new generation of integrated railway infrastructure.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we're building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com
.
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200121005201/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
